https://sputnikglobe.com/20210811/israel-allows-stem-cell-based-drug-against-covid-19-to-enter-phase-2-trials-reports-say-1083584589.html
Israel Allows Stem Cell-Based Drug Against COVID-19 to Enter Phase 2 Trials, Reports Say
Israel Allows Stem Cell-Based Drug Against COVID-19 to Enter Phase 2 Trials, Reports Say
Sputnik International
TEL AVIV (Sputnik) - The Israeli Health Ministry has given permission to biotech company Bonus BioGroup to begin Phase 2 trials of its COVID-19 drug based on... 11.08.2021, Sputnik International
2021-08-11T22:58+0000
2021-08-11T22:58+0000
2023-01-15T17:24+0000
middle east
world
newsfeed
covid-19
medications
stem cells
israel
https://cdn1.img.sputnikglobe.com/img/07e5/04/06/1082553470_0:228:3073:1956_1920x0_80_0_0_006cd149d82fe39dbd1cb7898d301fd8.jpg
In July, Israeli company Bonus BioGroup told Sputnik that it had successfully concluded Phase 1 trials of the drug, which were conducted at Rambam hospital in Haifa. According to the developers, three shots of the drug injected within 24 hours bring oxygen level in COVID-19 patient back to normal and significantly improve their well-being.Phase 2 trials will take place in Israel and involve 60 people experiencing severe cases of COVID-19. They will be followed by Phase 3 trials, which will include some 300 patients from different countries.The drug is produced from stem cells taken from healthy people, which then undergo treatment in a bioreactor. The entire process takes roughly 10 days.
israel
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
middle east, newsfeed, covid-19, medications, stem cells, israel
middle east, newsfeed, covid-19, medications, stem cells, israel
Israel Allows Stem Cell-Based Drug Against COVID-19 to Enter Phase 2 Trials, Reports Say
22:58 GMT 11.08.2021 (Updated: 17:24 GMT 15.01.2023) TEL AVIV (Sputnik) - The Israeli Health Ministry has given permission to biotech company Bonus BioGroup to begin Phase 2 trials of its COVID-19 drug based on stem cells, the Yedioth Ahronoth newspaper reported on Wednesday.
In July, Israeli company Bonus BioGroup told Sputnik that it had successfully concluded Phase 1 trials of the drug, which were conducted at Rambam hospital in Haifa. According to the developers, three shots of the drug injected within 24 hours bring oxygen level in COVID-19 patient back to normal and significantly improve their well-being.
Phase 2 trials will take place in Israel and involve 60 people experiencing
severe cases of COVID-19. They will be followed by Phase 3 trials, which will include some 300 patients from different countries.
The drug is produced from
stem cells taken from healthy people, which then undergo treatment in a bioreactor. The entire process takes roughly 10 days.
